CRISPR THERAPEUTICS AG Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
CRISPR THERAPEUTICS AG (CRSP) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $47.58 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- CRISPR THERAPEUTICS AG share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $46.59, a 10.67% increase year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $42.10, a 42.28% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $72.94, a 65.58% increase year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $44.05, a 24.85% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $47.76, a 23.46% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $62.40, a 37.23% increase from fiscal 2023.
- CRISPR THERAPEUTICS AG share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $45.47, a 24.46% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $60.19, a 51.58% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.58 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $46.59 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $47.76 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $41.91 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $41.58 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $42.10 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $62.40 10-K · filed 2026-02-12 | |||
| 2024-09-30 | $68.37 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $68.76 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $72.94 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $45.47 10-K · filed 2026-02-12 | |||
| 2023-09-30 | $45.72 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $45.58 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $44.05 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $60.19 10-K · filed 2025-02-11 | |||
| 2022-09-30 | $59.84 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | $59.67 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $58.62 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $124.32 10-K · filed 2024-02-21 | |||
| 2021-09-30 | $136.22 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $135.81 10-Q · filed 2021-07-29 | |||
| 2021-03-31 | $139.05 10-Q · filed 2021-04-27 | |||
| 2020-12-31 | $68.91 10-K · filed 2023-02-21 | |||
| 2020-09-30 | $56.19 10-Q · filed 2020-10-28 | |||
| 2020-06-30 | $48.18 10-Q · filed 2020-07-27 | |||
| 2020-03-31 | $45.73 10-Q · filed 2020-04-28 | |||
| 2019-12-31 | $39.16 10-K · filed 2022-02-15 | |||
| 2019-09-30 | $37.23 10-Q · filed 2019-10-28 | |||
| 2019-06-30 | $36.05 10-Q · filed 2019-07-29 | |||
| 2019-03-31 | $35.25 10-Q · filed 2019-04-29 | |||
| 2018-12-31 | $51.73 10-K · filed 2021-02-16 | |||
| 2017-12-31 | $16.98 10-K · filed 2020-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |